CV Outcome Trials with DPP-4 Inhibitors: Whats New?


Dr Ambrish Mithal, Gurugram    01 February 2018

mortality in patients with T2DM. Renal function decline is associated with increased risk of hospitalization and mortality.

Patients with T2DM and kidney disease are relatively under-represented population in CVOTs to date.

CARMELINA (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes mellitus at high vascular risk) is a long-term CVOT that is testing the impact of treatment with linagliptin vs. placebo, on top of standard of care, on CV outcomes and renal outcomes. This is a unique trial that will address important clinical questions.

CARMELINA includes the highest proportion of patients with established CKD compared with other DPP-4 inhibitor CVOTs. It will add evidence to the long-term clinical safety profile of linagliptin by including patients at advanced stages of kidney disease. It is the only DPP-4 inhibitor CVOT that will also test for renal outcomes.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.